SCHEIBLER LUKAS 4
4 · Apellis Pharmaceuticals, Inc. · Filed Apr 6, 2022
Insider Transaction Report
Form 4
SCHEIBLER LUKAS
See Remarks
Transactions
- Sale
Common Stock
2022-04-05$60.09/sh−609$36,593→ 52,233 total - Exercise/Conversion
Common Stock
2022-04-05$13.85/sh+609$8,435→ 52,842 total - Exercise/Conversion
Stock Option (Right to Buy)
2022-04-05−609→ 49,391 totalExercise: $13.85Exp: 2029-02-07→ Common Stock (609 underlying)
Footnotes (3)
- [F1]This is a scheduled exercise and sale from 10B5-1 trading plan.
- [F2]The sale price range within $1.00. Min. $60.00 - Max. $60.16.
- [F3]This represents a stock option grant made on 02/08/2019 that vests as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to the satisfaction of a specified performance condition and continued service.